Innoviva Quick Ratio 2012-2026 | INVA
Historical quick ratio values for Innoviva (INVA) over the last 10 years.
| Innoviva Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2026-03-31 | $0.73B | $0.04B | 20.07 |
| 2025-12-31 | $0.69B | $0.05B | 13.85 |
| 2025-09-30 | $0.65B | $0.05B | 13.33 |
| 2025-06-30 | $0.60B | $0.25B | 2.45 |
| 2025-03-31 | $0.54B | $0.24B | 2.30 |
| 2024-12-31 | $0.52B | $0.24B | 2.21 |
| 2024-09-30 | $0.37B | $0.22B | 1.64 |
| 2024-06-30 | $0.32B | $0.03B | 11.40 |
| 2024-03-31 | $0.27B | $0.03B | 9.17 |
| 2023-12-31 | $0.30B | $0.04B | 7.96 |
| 2023-09-30 | $0.26B | $0.04B | 7.31 |
| 2023-06-30 | $0.28B | $0.04B | 7.02 |
| 2023-03-31 | $0.25B | $0.04B | 6.47 |
| 2022-12-31 | $0.39B | $0.14B | 2.87 |
| 2022-09-30 | $0.38B | $0.16B | 2.34 |
| 2022-06-30 | $0.00B | $0.13B | 0.00 |
| 2022-03-31 | $0.00B | $0.11B | 0.00 |
| 2021-12-31 | $0.00B | $0.01B | 0.00 |
| 2021-09-30 | $0.00B | $0.00B | 0.00 |
| 2021-06-30 | $0.00B | $0.01B | 0.00 |
| 2021-03-31 | $0.00B | $0.00B | 0.00 |
| 2020-12-31 | $0.00B | $0.01B | 0.00 |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2020-06-30 | $0.00B | $0.01B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | $0.01B | 0.00 |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2019-06-30 | $0.00B | $0.01B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.00B | $0.01B | 0.00 |
| 2018-09-30 | $0.00B | $0.00B | 0.00 |
| 2018-06-30 | $0.00B | $0.01B | 0.00 |
| 2018-03-31 | $0.00B | $0.00B | 0.00 |
| 2017-12-31 | $0.00B | $0.04B | 0.00 |
| 2017-09-30 | $0.00B | $0.03B | 0.00 |
| 2017-06-30 | $0.00B | $0.03B | 0.00 |
| 2017-03-31 | $0.00B | $0.02B | 0.00 |
| 2016-12-31 | $0.00B | $0.02B | 0.00 |
| 2016-09-30 | $0.00B | $0.02B | 0.00 |
| 2016-06-30 | $0.00B | $0.02B | 0.00 |
| 2016-03-31 | $0.00B | $0.01B | 0.00 |
| 2015-12-31 | $0.00B | $0.01B | 0.00 |
| 2015-09-30 | $0.00B | $0.01B | 0.00 |
| 2015-06-30 | $0.00B | $0.01B | 0.00 |
| 2015-03-31 | $0.00B | $0.01B | 0.00 |
| 2014-12-31 | $0.00B | $0.01B | 0.00 |
| 2014-09-30 | $0.00B | $0.04B | 0.00 |
| 2014-06-30 | $0.00B | $0.05B | 0.00 |
| 2014-03-31 | $0.38B | $0.04B | 8.57 |
| 2013-12-31 | $0.47B | $0.08B | 5.60 |
| 2013-09-30 | $0.51B | $0.04B | 13.28 |
| 2013-06-30 | $0.45B | $0.04B | 11.62 |
| 2013-03-31 | $0.47B | $0.03B | 15.83 |
| 2012-12-31 | $0.25B | $0.03B | 8.46 |
| 2012-09-30 | $0.28B | $0.03B | 10.24 |
| 2012-06-30 | $0.30B | $0.03B | 11.60 |
| 2012-03-31 | $0.00B | $0.03B | 0.00 |
| 2011-12-31 | $0.00B | $0.05B | 0.00 |
| 2011-09-30 | $0.00B | $0.04B | 0.00 |
| 2011-06-30 | $0.00B | $0.04B | 0.00 |
| 2011-03-31 | $0.00B | $0.03B | 0.00 |
| 2010-12-31 | $0.00B | $0.04B | 0.00 |
| 2010-09-30 | $0.00B | $0.04B | 0.00 |
| 2010-06-30 | $0.00B | $0.04B | 0.00 |
| 2010-03-31 | $0.00B | $0.04B | 0.00 |
| 2009-12-31 | $0.00B | $0.04B | 0.00 |
| 2009-09-30 | $0.00B | $0.04B | 0.00 |
| 2009-06-30 | $0.00B | $0.04B | 0.00 |
| 2009-03-31 | $0.00B | $0.04B | 0.00 |
| 2008-12-31 | $0.00B | $0.04B | 0.00 |
| 2008-09-30 | $0.00B | $0.04B | 0.00 |
| 2008-06-30 | $0.00B | $0.05B | 0.00 |
| 2008-03-31 | $0.00B | $0.05B | 0.00 |
| 2007-12-31 | $0.00B | $0.06B | 0.00 |
| 2007-09-30 | $0.00B | $0.06B | 0.00 |
| 2007-06-30 | $0.00B | $0.06B | 0.00 |
| 2007-03-31 | $0.00B | $0.06B | 0.00 |
| 2006-12-31 | $0.00B | $0.06B | 0.00 |
| 2006-09-30 | $0.00B | $0.06B | 0.00 |
| 2006-06-30 | $0.00B | $0.05B | 0.00 |
| 2006-03-31 | $0.00B | $0.05B | 0.00 |
| 2005-12-31 | $0.00B | $0.05B | 0.00 |
| 2005-09-30 | $0.00B | $0.04B | 0.00 |
| 2005-06-30 | $0.00B | $0.04B | 0.00 |
| 2005-03-31 | $0.00B | $0.04B | 0.00 |
| 2004-12-31 | $0.00B | $0.03B | 0.00 |
| 2004-09-30 | $0.00B | $0.03B | 0.00 |
| 2004-06-30 | $0.00B | 0.00 | |
| 2004-03-31 | $0.00B | 0.00 | |
| 2003-09-30 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |